The Weill Cornell Medicine Lymphoma Program has recently opened a new clinical trial for men and women with relapsed/refractory lymphoma. The study sponsor is PIQUR Therapeutics AG, and the principal investigator at Weill Cornell is Lisa Roth M.D. For more information about the study, please call Catherine Babaran, RN at 212-746-2651 or e-mail Catherine at email@example.com.
Men and women age 18 and older with histologically confirmed diagnosis of relapsed or refractory lymphoma who have received at least two prior lines of therapy including immuno-chemotherapy. Patients with relapsed chronic lymphoid leukemia (CLL) are eligible if they have received one or more prior lines of any approved standard therapy.
Detailed eligibility reviewed when you contact the study team.
This clinical trial is for men and women with relapsed or refractory lymphoma. Despite conventional therapies, such as chemotherapy and radiation therapy, the treatment of lymphomas remains challenging, with the disease relapsing in many patients, which is subsequently more difficult to treat. The main goal of this study is to investigate the efficacy of PQR309 in patients with relapsed or refractory lymphomas. This is an open-label, non-randomized, multicenter phase 2 study with a safety run-in evaluating efficacy and safety of PQR309 in patients with relapsed or refractory lymphoma. There will be a safety run-in phase with up to 12 patients treated with 60 or 80 milligrams every day and then a Phase 2 expansion phase conducted with the highest dose level considered to be safe. Patients will take 60 mg or 80 mg PQR309 orally once daily and will continue treatment as long as they are responding to therapy and not experiencing unacceptable side effects.
As the Director of the Adolescent and Young Adults (AYA) Lymphoma Program, Dr. Lisa Roth has a unique ability to empathize with her patients. Three years ago, Dr. Roth herself was diagnosed with lymphoma. As an oncologist, she was used to confronting cancer every day, but never on such a deeply personal level. Not unlike many of her patients, she went from being young and healthy to facing a life-threatening illness with no warning.
After successfully undergoing chemotherapy, Dr. Roth’s lymphoma was in remission and she made running part of her recovery process. Six months after finishing cancer treatment, she ran her first race in the New York Road Runners Mini 10K.
Last weekend Dr. Roth returned to run the 2016 Mini 10K, but this year she was running for one of her precocious pediatric patients.
For Sammy, a six-year-old who has been battling leukemia for almost two years, his days are filled with not only play dates, ninjas and superheroes, but also routine visits to Weill Cornell and NewYork Presbyterian Hospital for chemotherapy and other procedures related to his diagnosis.
“Sammy and his family are a true inspiration,” says Roth. As part of “Team Sammy” Dr. Roth, along with Sammy’s mom Mana and a team of 12 people, ran the 10K and raised nearly $18,000 for the Leukemia and Lymphoma Society, proving you don’t need superpowers to make a difference in the fight against blood cancer.
For Dr. Roth, it’s also personal. “This was my first race as a new mom. I owe my life and opportunity to be a mom to research funded by groups like the Leukemia & Lymphoma Society,” says Roth.
Every year nearly 70,000 adolescents and young adults (AYAs) are diagnosed with cancer in the United States. Of these, lymphoma is the most common. Teenagers and young adults with lymphoma have different needs than other cancer patients. Treatment can affect your education, career, fertility, and independence, which can be challenging for both patients and their families. Because of this, adolescents and young adults with lymphoma often feel lost – not quite fitting in at pediatric or adult treatment centers.